Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS IV: Duration of Androgen Blockade in High-Risk Prostate Cancer
NCT00223171Phase 3Active, not recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Oct 2000
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Université de Sherbrooke. Primary endpoints: Specific Survival at 10 years, Overall Survival at 10 years and 1 more. Started Oct 2000; status: active, not recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00223171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223171.